{ "@context": "https://frontierpicks.com/schemas/dossier.v1.json", "ticker": "QSI", "name": "Quantum-Si Incorporated", "url": "https://frontierpicks.com/dossiers/QSI/", "json_url": "https://frontierpicks.com/dossiers/QSI.json", "status": "DORMANT", "current_conviction": "LOW", "archetype": { "code": "a5", "n": 5 }, "current_thesis": "Quantum-Si's shares still price in more than its Proteus protein sequencer has delivered: launch is guided for Q2 2027 and 2026 revenue for about $1.0M. The 5 November 2026 third-quarter report tests the launch date, the cash runway and any share sales.", "invalidation_trigger": "A daily close below $1.00, which would erase most of the post-HUPO gain and put the shares back under Nasdaq's $1 minimum bid. Separately, any delay of the Proteus launch beyond Q2 2027.", "catalyst_date": "2026-11-05", "pick": null, "themes": [], "tags": [], "sources": [], "notes": [ "The Proteus performance data released 2026-09-29 came from an 18-amino-acid developmental kit. The commercial launch kit is expected to cover all 20 amino acids.", "Quantum-Si has two share classes: 198.9M Class A and 19.9M Class B shares were outstanding at 2026-06-30. The Class B shares carry enhanced voting rights.", "FY2026 revenue guidance is about $1.0M while customers move from Platinum Pro to Proteus, so reported sales say little about the platform until launch.", "Quantum-Si has a $100M at-the-market stock program and a $300M shelf registration on file from 2025. Share sales under it can occur without a separate announcement.", "Quantum-Si regained compliance with Nasdaq's $1 minimum bid on 2026-10-15. A new deficiency would follow 30 consecutive business days of closing bids below $1.00." ], "source_links": [], "body_markdown": "## Current Thesis\nQuantum-Si's shares still price in more than the business has shown: the Proteus protein sequencer is guided to launch in the second quarter of 2027, and 2026 revenue is guided to about $1.0M. The third-quarter report on 2026-11-05 settles whether the launch date, the cash runway and the share count hold.\n\nThe shares closed at $1.46 on 2026-10-30, adjusted daily closes, up from $1.09 on 2026-10-19. The 14-day relative strength index was 53.4, a neutral reading. Nothing in company filings or releases since 2026-10-16 explains the rebound, and the engineering case has not changed since the 19-amino-acid result of 2026-10-08.\n\nThe narrative is maturing: the World HUPO (Human Proteome Organization) data of 2026-09-29 and the 19-amino-acid milestone are well known, and the price has swung between $1.09 and $1.55 in a month with no new company data. Revenue stays near zero until launch, so the schedule and the cash decide the case.\n\n## Bull Case\n- **Chemistry milestones are arriving early.** Quantum-Si reported 18 amino acids on 2026-09-15 and 19 on 2026-10-08. Management said all 20 are \"well within reach by year-end 2026\".\n- **Large gain over the current instrument.** The 2026-09-29 HUPO release reported a median of 30 times more alignments than Platinum Pro from a single chamber. The false discovery rate was 1.36%, against 6.58% for Platinum Pro.\n- **Listing risk is cleared for now.** On 2026-10-15 Quantum-Si said Nasdaq had confirmed it regained compliance with the $1.00 minimum bid price, closing a deficiency noticed on 2026-07-23.\n- **Cash reaches past the launch.** Cash and marketable securities were $169.9M on 2026-06-30. Management expects that to fund operations into the fourth quarter of 2028 (Form 8-K, 2026-08-13).\n- **Analyst support held after the data.** HC Wainwright reiterated a Buy rating and a $4 price target on 2026-09-29, Benzinga reported.\n\n## Bear Case\n- **The launch has already slipped once.** On 2026-08-13 Quantum-Si moved the Proteus launch to Q2 2027 to add an integrated instrument design cycle. The same release announced a 20% workforce reduction.\n- **19 amino acids is a lab result.** The 2026-10-08 release says the company is still working to put the capability into a developmental sequencing kit, with no date. The HUPO figures came from the older 18-amino-acid kit.\n- **The headline data are partly projected.** The 2026-09-29 release says the instrument, consumables and software are not fully optimized. The full-run figure of about 60 times more alignments is projected from single-chamber results.\n- **Losses dwarf sales.** Second-quarter 2026 revenue was $344 thousand, down from $591 thousand a year earlier. The net loss was $23.5M (Form 8-K, 2026-08-13).\n- **A share-sale program is in place.** Quantum-Si has a $100M at-the-market stock program and a $300M shelf registration filed in 2025. Sales during the October price swings would first appear in the third-quarter 10-Q.\n\n## Setup & Price Structure\nThe shares closed at $1.46 on 2026-10-30. That is 32.1% below the 52-week high of $2.15 and 90.7% above the close three months earlier, on adjusted daily closes. The highest close of the October rally was $1.55 on 2026-10-02; the lowest close since was $1.09 on 2026-10-19.\n\nThe $1.00 level is the Nasdaq minimum bid price. A new deficiency notice would follow 30 consecutive business days of closing bids below it. The 2026-11-05 report falls five sessions after the latest close, so the next large price move is likely to come from the report.\n\nCrowding evidence: Benzinga flagged Quantum-Si on 2026-10-05 among health care stocks with relative strength readings above 80, an overbought level. The reading has since cooled to 53.4. The at-the-market program means share issuance into strength is possible and would be visible only in the quarterly filing.\n\n## Catalyst Calendar (next 30 days)\n\n- **~2026-11-05 to 2026-11-14 (est.):** Form 10-Q, which discloses the share count and any stock sold under the at-the-market program.\n- **2026-12-31:** Company target for detecting all 20 amino acids, just outside the 30-day window but the milestone the launch kit depends on.\n\n## Elapsed catalysts\n\n- **Early November 2026 (est.):** Proteus roadshow stops in Munich and Berlin, per a company release of 2026-09-09. Customer feedback is the only commercial signal before launch. *(passed 58d ago)*\n- **2026-11-05:** Third-quarter 2026 results and business update. Shows the launch timing, quarterly cash burn against the Q4 2028 runway, and any at-the-market sales. *(passed 1d ago)*\n\n## What Would Change Our Mind\nThe case breaks if the 2026-11-05 report pushes the Proteus launch beyond the second quarter of 2027, or if it shows large at-the-market sales that raise the share count before any launch revenue. A missed or deferred year-end target for all 20 amino acids would point the same way.\n\nA daily close below $1.00 would put the shares back under Nasdaq's minimum bid and erase most of the post-HUPO gain. A developmental-kit update showing 19 or 20 amino acids on an integrated instrument, with the launch date intact and no meaningful dilution, would strengthen the case.\n\n## Correlation Notes\nQuantum-Si trades on its own news flow rather than with an index or sector. The 24% jump on 2026-09-29 followed the HUPO data release, and the October reversal followed no company announcement. Peers in protein analysis and life-science tools, and small-cap healthcare names with high retail attention, are the closest comparison. The sample of moves is too small to measure a stable relationship.", "first_seen": "2026-09-30", "last_analyzed": "2026-11-02T05:20:39+00:00", "last_synthesized": "2026-11-02", "last_update_source": "watchlist_research", "license": "Content © FrontierPicks. Cite the canonical URL." }